

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE SIX MONTHS ENDED JUNE 30, 2024

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the “**Company**”) pursuant to the Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.

The major financial data of the Company and its subsidiaries (together, the “**Group**”) for the six months ended June 30, 2024 as set out in this announcement are preliminary financial data prepared in accordance with the International Financial Reporting Standards, and have not been audited by the auditor of the Company. As a result, there may be differences between the financial data mentioned in this announcement and those to be disclosed in the interim results announcement of the Group for the six months ended June 30, 2024. The final interim data should be those to be disclosed in the latter. Investors are hereby reminded of the investment risks.

I. ESTIMATED RESULTS FOR THE PERIOD

(I) Period of estimated results

From January 1, 2024 to June 30, 2024

(II) Estimated Results

1. It is expected that the revenue of the Group in the first half of 2024 will be ranging from approximately RMB405.5 million to RMB415.5 million and will increase by approximately RMB78.7 million to RMB88.7 million as compared with the data in the financial statements for the corresponding period of last year, representing a year-on-year increase of approximately 24.1% to 27.1%.
2. It is expected that the research and development (“**R&D**”) expenses of the Group in the first half of 2024 will be ranging from approximately RMB156.7 million to RMB166.7 million and will decrease by approximately RMB81.3 million to RMB91.3 million as compared with the data in the financial statements for the corresponding period of last year, representing a year-on-year decrease of approximately 32.8% to 36.8%.

3. It is expected that the loss of the Group for the six months ended June 30, 2024 will be ranging from approximately RMB44.7 million to RMB54.7 million and will decrease by approximately RMB135.1 million to RMB145.1 million as compared with the data in the financial statements for the corresponding period of last year, representing a year-on-year decrease of approximately 71.2% to 76.4%.

II. INTERIM UNAUDITED RESULTS FOR THE CORRESPONDING PERIOD OF LAST YEAR

- (I) **The revenue of the Group for the six months ended June 30, 2023:** Approximately RMB326.8 million
- (II) **The research and development expenses of the Group for the six months ended June 30, 2023:** Approximately RMB248.0 million
- (III) **The loss for the period of the Group for the six months ended June 30, 2023:** Approximately RMB189.8 million

III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS DURING THE PERIOD

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company considers that the revenue of the Company maintained a good growth, the substantial decrease in loss is mainly attributable to the following factors:

- (I) With the Project Integrum (千鼠萬抗) having been completed by stages, the Company has established a shelf-ready library containing over 400,000 fully human antibody sequences, and can directly carry out large-scale licensing cooperation of antibody molecules with external parties. The high-margin antibody licensing business has now become one of the core driving forces for the rapid business growth of the Company. In the first half of 2024, the number of external co-development/out-licensing/transfer agreements signed in respect of non-core products and the revenue attributed to the antibody licensing business have each maintained a high growth rate;
- (II) Leveraging on our robust gene-editing technology platform, the Company continues to self-develop various high-end animal models and provides such innovative models to domestic and international pharmaceutical clients. In the first half of 2024, the animal model sales business has continued to maintain a positive growth trend while maintaining high levels of gross profit;
- (III) With the continuous overseas market development, expansion and adjustments in the overseas sales teams, the Company has gradually improved the layout of its global sales system. In the first half of 2024, the Company’s overseas business has continued to maintain rapid growth, and the proportion of the overseas business sales is expected to further increase;
- (IV) With the large-scale R&D investment phase having been concluded, the R&D investment in the first half of 2024 is expected to continue to decline significantly on a year-over-year basis. In the future, the investments in R&D resources of the Company is expected to be more catered forwards the R&D areas that support the rapid development of the core business of the Company; and

- (V) In addition, the Company has also taken measures to continuously improve its assets utilization rate and operating efficiency, so as to reduce operating costs while maintaining rapid growth of various businesses.

IV. RISK WARNING

The above preliminary financial data are only preliminary accounting data, which has not been audited by the auditor of the Company. The final interim financial data will be disclosed in the interim results announcement of the Group for the six months ended June 30, 2024 and the 2024 interim report. Investors are advised to pay attention to such investment risks.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, August 7, 2024

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.